New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment